Last reviewed · How we verify

Procedural sedation with ketamine-propofol combination

Centre Hospitalier Universitaire de Nice · FDA-approved active Small molecule Quality 1/100

Procedural sedation with ketamine-propofol combination is a Small molecule drug developed by Centre Hospitalier Universitaire de Nice. It is currently FDA-approved.

At a glance

Generic nameProcedural sedation with ketamine-propofol combination
SponsorCentre Hospitalier Universitaire de Nice
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Procedural sedation with ketamine-propofol combination

What is Procedural sedation with ketamine-propofol combination?

Procedural sedation with ketamine-propofol combination is a Small molecule drug developed by Centre Hospitalier Universitaire de Nice.

Who makes Procedural sedation with ketamine-propofol combination?

Procedural sedation with ketamine-propofol combination is developed and marketed by Centre Hospitalier Universitaire de Nice (see full Centre Hospitalier Universitaire de Nice pipeline at /company/centre-hospitalier-universitaire-de-nice).

What development phase is Procedural sedation with ketamine-propofol combination in?

Procedural sedation with ketamine-propofol combination is FDA-approved (marketed).

Related